<?xml version='1.0' encoding='utf-8'?>
<document id="30117405"><sentence text="In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone."><entity charOffset="44-53" id="DDI-PubMed.30117405.s1.e0" text="Sulfoxide" /><entity charOffset="61-68" id="DDI-PubMed.30117405.s1.e1" text="Sulfone" /><entity charOffset="84-95" id="DDI-PubMed.30117405.s1.e2" text="Albendazole" /><entity charOffset="97-112" id="DDI-PubMed.30117405.s1.e3" text="Triclabendazole" /><entity charOffset="115-123" id="DDI-PubMed.30117405.s1.e4" text="Aldicarb" /><entity charOffset="125-135" id="DDI-PubMed.30117405.s1.e5" text="Methiocarb" /><entity charOffset="137-148" id="DDI-PubMed.30117405.s1.e6" text="Montelukast" /><entity charOffset="153-164" id="DDI-PubMed.30117405.s1.e7" text="Ziprasidone" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e0" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e1" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e2" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e3" e2="DDI-PubMed.30117405.s1.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e3" e2="DDI-PubMed.30117405.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e3" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e3" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e3" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e4" e2="DDI-PubMed.30117405.s1.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e4" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e4" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e4" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e5" e2="DDI-PubMed.30117405.s1.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e5" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e5" e2="DDI-PubMed.30117405.s1.e7" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e6" e2="DDI-PubMed.30117405.s1.e6" /><pair ddi="false" e1="DDI-PubMed.30117405.s1.e6" e2="DDI-PubMed.30117405.s1.e7" /></sentence><sentence text="The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process" /><sentence text=" Although many drugs can be metabolized to sulfoxide and/or sulfone metabolites, seldom is known on the CYP inhibition potential and/or the metabolic fate for such metabolites"><entity charOffset="43-52" id="DDI-PubMed.30117405.s3.e0" text="sulfoxide" /><entity charOffset="60-67" id="DDI-PubMed.30117405.s3.e1" text="sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s3.e0" e2="DDI-PubMed.30117405.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s3.e0" e2="DDI-PubMed.30117405.s3.e1" /></sentence><sentence text="" /><sentence text="The key objectives were: a) to evaluate the in vitro CYP inhibition potential of selected parent drugs with sulfoxide/sulfone metabolites; b) to assess the in vitro metabolic fate of the same panel of parent drugs and metabolites"><entity charOffset="108-117" id="DDI-PubMed.30117405.s5.e0" text="sulfoxide" /><entity charOffset="118-125" id="DDI-PubMed.30117405.s5.e1" text="sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s5.e0" e2="DDI-PubMed.30117405.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s5.e0" e2="DDI-PubMed.30117405.s5.e1" /></sentence><sentence text="" /><sentence text="In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)"><entity charOffset="277-280" id="DDI-PubMed.30117405.s7.e0" text="FMO" /><entity charOffset="282-284" id="DDI-PubMed.30117405.s7.e1" text="AO" /><entity charOffset="290-291" id="DDI-PubMed.30117405.s7.e2" text="AO" /><pair ddi="false" e1="DDI-PubMed.30117405.s7.e0" e2="DDI-PubMed.30117405.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s7.e0" e2="DDI-PubMed.30117405.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s7.e0" e2="DDI-PubMed.30117405.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s7.e1" e2="DDI-PubMed.30117405.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s7.e1" e2="DDI-PubMed.30117405.s7.e2" /></sentence><sentence text=" All samples were analysed by LC-MS-MS method" /><sentence text="" /><sentence text="CYP1A2 was inhibited by methiocarb, triclabendazole, triclabendazole sulfoxide, and ziprasidone sulfone with IC50 of 0"><entity charOffset="24-34" id="DDI-PubMed.30117405.s10.e0" text="methiocarb" /><entity charOffset="36-51" id="DDI-PubMed.30117405.s10.e1" text="triclabendazole" /><entity charOffset="53-78" id="DDI-PubMed.30117405.s10.e2" text="triclabendazole sulfoxide" /><entity charOffset="84-103" id="DDI-PubMed.30117405.s10.e3" text="ziprasidone sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e0" e2="DDI-PubMed.30117405.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e0" e2="DDI-PubMed.30117405.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e0" e2="DDI-PubMed.30117405.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e0" e2="DDI-PubMed.30117405.s10.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e1" e2="DDI-PubMed.30117405.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e1" e2="DDI-PubMed.30117405.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e1" e2="DDI-PubMed.30117405.s10.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e2" e2="DDI-PubMed.30117405.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s10.e2" e2="DDI-PubMed.30117405.s10.e3" /></sentence><sentence text="71 µM, 1" /><sentence text="07 µM, 4" /><sentence text="19 µM, and 17" /><sentence text="14 µM, respectively" /><sentence text=" CYP2C8 was inhibited by montelukast, montelukast sulfoxide, montelukast sulfone, tribendazole, triclabendazole sulfoxide, and triclabendazole sulfone with IC50 of 0"><entity charOffset="25-36" id="DDI-PubMed.30117405.s15.e0" text="montelukast" /><entity charOffset="38-59" id="DDI-PubMed.30117405.s15.e1" text="montelukast sulfoxide" /><entity charOffset="61-80" id="DDI-PubMed.30117405.s15.e2" text="montelukast sulfone" /><entity charOffset="82-94" id="DDI-PubMed.30117405.s15.e3" text="tribendazole" /><entity charOffset="96-121" id="DDI-PubMed.30117405.s15.e4" text="triclabendazole sulfoxide" /><entity charOffset="127-150" id="DDI-PubMed.30117405.s15.e5" text="triclabendazole sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e0" e2="DDI-PubMed.30117405.s15.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e1" e2="DDI-PubMed.30117405.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e1" e2="DDI-PubMed.30117405.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e1" e2="DDI-PubMed.30117405.s15.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e1" e2="DDI-PubMed.30117405.s15.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e1" e2="DDI-PubMed.30117405.s15.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e2" e2="DDI-PubMed.30117405.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e2" e2="DDI-PubMed.30117405.s15.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e2" e2="DDI-PubMed.30117405.s15.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e2" e2="DDI-PubMed.30117405.s15.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e3" e2="DDI-PubMed.30117405.s15.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e3" e2="DDI-PubMed.30117405.s15.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e3" e2="DDI-PubMed.30117405.s15.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e4" e2="DDI-PubMed.30117405.s15.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s15.e4" e2="DDI-PubMed.30117405.s15.e5" /></sentence><sentence text="08 µM, 0" /><sentence text="05 µM, 0" /><sentence text="02 µM, 3" /><sentence text="31 µM, 8" /><sentence text="95 µM, and 1" /><sentence text="05 µM, respectively" /><sentence text=" CYP2C9 was inhibited by triclabendazole, triclabendazole sulfoxide, triclabendazole sulfone, montelukast, montelukast sulfoxide and montelukast sulfone with IC50 of 1"><entity charOffset="25-40" id="DDI-PubMed.30117405.s22.e0" text="triclabendazole" /><entity charOffset="42-67" id="DDI-PubMed.30117405.s22.e1" text="triclabendazole sulfoxide" /><entity charOffset="69-92" id="DDI-PubMed.30117405.s22.e2" text="triclabendazole sulfone" /><entity charOffset="94-105" id="DDI-PubMed.30117405.s22.e3" text="montelukast" /><entity charOffset="107-128" id="DDI-PubMed.30117405.s22.e4" text="montelukast sulfoxide" /><entity charOffset="133-152" id="DDI-PubMed.30117405.s22.e5" text="montelukast sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e0" e2="DDI-PubMed.30117405.s22.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e1" e2="DDI-PubMed.30117405.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e1" e2="DDI-PubMed.30117405.s22.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e1" e2="DDI-PubMed.30117405.s22.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e1" e2="DDI-PubMed.30117405.s22.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e1" e2="DDI-PubMed.30117405.s22.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e2" e2="DDI-PubMed.30117405.s22.e2" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e2" e2="DDI-PubMed.30117405.s22.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e2" e2="DDI-PubMed.30117405.s22.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e2" e2="DDI-PubMed.30117405.s22.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e3" e2="DDI-PubMed.30117405.s22.e3" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e3" e2="DDI-PubMed.30117405.s22.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e3" e2="DDI-PubMed.30117405.s22.e5" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e4" e2="DDI-PubMed.30117405.s22.e4" /><pair ddi="false" e1="DDI-PubMed.30117405.s22.e4" e2="DDI-PubMed.30117405.s22.e5" /></sentence><sentence text="17 µM, 1" /><sentence text="95 µM, 0" /><sentence text="69 µM, 1" /><sentence text="34 µM, 3" /><sentence text="61 µM and 2" /><sentence text="15 µM, respectively" /><sentence text=" CYP2C19 was inhibited by triclabendazole and triclabendazole sulfoxide with IC50 of 0"><entity charOffset="26-41" id="DDI-PubMed.30117405.s29.e0" text="triclabendazole" /><entity charOffset="46-71" id="DDI-PubMed.30117405.s29.e1" text="triclabendazole sulfoxide" /><pair ddi="false" e1="DDI-PubMed.30117405.s29.e0" e2="DDI-PubMed.30117405.s29.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s29.e0" e2="DDI-PubMed.30117405.s29.e1" /></sentence><sentence text="25 and 0" /><sentence text="22, respectively" /><sentence text=" CYP3A4 was inhibited by montelukast sulfoxide and triclabendazole with IC50 of 9"><entity charOffset="25-46" id="DDI-PubMed.30117405.s32.e0" text="montelukast sulfoxide" /><entity charOffset="51-66" id="DDI-PubMed.30117405.s32.e1" text="triclabendazole" /><pair ddi="false" e1="DDI-PubMed.30117405.s32.e0" e2="DDI-PubMed.30117405.s32.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s32.e0" e2="DDI-PubMed.30117405.s32.e1" /></sentence><sentence text="33 and 15" /><sentence text="11, respectively" /><sentence text=" Amongst the studied sulfoxide/sulfone substrates, the propensity of involvement of CY2C9 and CYP3A4 enzyme was high (approximately 56% of total) in the metabolic fate experiments"><entity charOffset="21-30" id="DDI-PubMed.30117405.s35.e0" text="sulfoxide" /><entity charOffset="31-38" id="DDI-PubMed.30117405.s35.e1" text="sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s35.e0" e2="DDI-PubMed.30117405.s35.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s35.e0" e2="DDI-PubMed.30117405.s35.e1" /></sentence><sentence text="" /><sentence text="Based on the findings, a proper risk assessment strategy needs to be factored (i" /><sentence text="e" /><sentence text=", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy"><entity charOffset="113-122" id="DDI-PubMed.30117405.s39.e0" text="sulfoxide" /><entity charOffset="123-130" id="DDI-PubMed.30117405.s39.e1" text="sulfone" /><pair ddi="false" e1="DDI-PubMed.30117405.s39.e0" e2="DDI-PubMed.30117405.s39.e0" /><pair ddi="false" e1="DDI-PubMed.30117405.s39.e0" e2="DDI-PubMed.30117405.s39.e1" /></sentence><sentence text="" /></document>